Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted),selvacovatein,damlecovatein, Date of authorisation: 30/03/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted),selvacovatein,damlecovatein, Date of authorisation: 30/03/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted),selvacovatein,damlecovatein, Date of authorisation: 30/03/2023, Revision: 8, Status: Authorised
